PET/MRI Imaging of Glutamate Release in the Brain

PET/MRI Imaging of Glutamate Release in the Brain of Healthy Controls

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02511691

Enrollment

Registered

2015-07-30

Start date

2015-07-31

Completion date

2016-03-03

Last updated

2020-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Based on PET (18-PSS232) and MRI, glutamate release after N-acetylcystein challenge will be monitored in human brains.

Detailed description

Diagnostic trial with quantification of glutamate release in PET/MR.

Interventions

DRUG18F-PSS232

Diagnostic PET Tracer

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy volunteer

Exclusion criteria

* smoker * drug addiction * significant neurological or psychiatric conditions

Design outcomes

Primary

Measure	Time frame	Description
Difference of Binding Potentials of 18F-PSS232 in different brain regions between Baseline PET and PET after medical challenge	Baseline PET and PET after medical challenge will be scanned within 3 months	for details, please see Innis: Journal of Cerebral Blood Flow & Metabolism (2007) 27, 1533-1539

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026